Development and characterization of a fully functional small anti-HER2 antibody

BMB Reports

Volumn 42, Issue 10, 2009, Pages 636-641

  Gao, Jie ^a   Li, Bohua ^a,b   Li, Huimei ^a   Zhang, Xunmin ^a   Zhang, Dapeng ^a,b   Zhao, Lei ^a   Wang, Chong ^c   Fang, Chen ^a   Qian, Weizhu ^a,b   Hou, Sheng ^a,b   Kou, Geng ^a,b   Wei, Huafeng ^a   Shi, Shu ^a   Wang, Hao ^a,b   Guo, Yajun ^a,b  

^a SECOND MILITARY MEDICAL UNIVERSITY   (China)

^b National Engineering Research Center for Antibody Medicine   (China)

^c SHANGHAI JIAO TONG UNIVERSITY SCHOOL OF MEDICINE   (China)

Author keywords

Breast cancer; Complementarity determining regions; Monoclonal antibody; Rational design; Trastuzumab

Indexed keywords

ANTIBODY; ANTIGEN; EPIDERMAL GROWTH FACTOR RECEPTOR 2; FC RECEPTOR; FLUORESCEIN ISOTHIOCYANATE; MONOCLONAL ANTIBODY; TRASTUZUMAB;

ANTIBODY DEPENDENT CELLULAR CYTOTOXICITY; ANTIBODY SPECIFICITY; ARTICLE; BREAST TUMOR; CELL PROLIFERATION; FEMALE; HUMAN; IMMUNOLOGY; METABOLISM; METHODOLOGY; MOLECULAR BIOLOGY; MOLECULAR MIMICRY; TUMOR CELL LINE;

ANTIBODIES; ANTIBODIES, MONOCLONAL; ANTIBODY SPECIFICITY; ANTIBODY-DEPENDENT CELL CYTOTOXICITY; ANTIGENS; BREAST NEOPLASMS; CELL LINE, TUMOR; CELL PROLIFERATION; FEMALE; FLUORESCEIN-5-ISOTHIOCYANATE; HUMANS; MOLECULAR BIOLOGY; MOLECULAR MIMICRY; RECEPTOR, ERBB-2; RECEPTORS, FC;

EID: 75649104332     PISSN: 19766696     EISSN: 1976670X     Source Type: Journal    
DOI: 10.5483/BMBRep.2009.42.10.636     Document Type: Article

References (21)

1. Adams, G. P. and Weiner, L. M. (2005) Monoclonal antibody therapy of cancer. Nat. Biotechnol. 23, 1147-1157.
2. Jang, S. H., Wientjes, M. G., Lu, D. and Au, J. L. (2003) Drug delivery and transport to solid tumors. Pharm. Res. 20, 1337-1350.
3. Beckman, R. A., Weiner, L. M. and Davis, H. M. (2007) Antibody constructs in cancer therapy: protein engineering strategies to improve exposure in solid tumors. Cancer 109, 170-179.
4. Graff, C. P. and Wittrup, K. D. (2003) Theoretical analysis of antibody targeting of tumor spheroids: importance of dosage for penetration, and affinity for retention. Cancer Res. 63, 1288-1296.
5. Kortt, A. A., Dolezal, O., Power, B. E. and Hudson, P. J. (2001) Dimeric and trimeric antibodies: high avidity scFvs for cancer targeting. Biomol. Eng. 18, 95-108.
6. Holt, L. J., Herring, C., Jespers, L. S., Woolven, B. P. and Tomlinson, I. M. (2003) Domain antibodies: proteins for therapy. Trends Biotechnol. 21, 484-490.
7. Qiu, X. Q., Wang, H., Cai, B., Wang, L. L. and Yue, S. T. (2007) Small antibody mimetics comprising two complementarity-determining regions and a framework region for tumor targeting. Nat. Biotechnol. 25, 921-929.
8. Ladner, R. C. (2007) Antibodies cut down to size. Nat. Biotechnol. 25, 875-877.
9. Casset, F., Roux, F., Mouchet, P., Bes, C., Chardes, T., Granier, C., Mani, J. C., Pugnière, M., Laune, D., Pau, B., Kaczorek, M., Lahana, R. and Rees, A. (2003) A peptide mimetic of an anti-CD4 monoclonal antibody by rational design. Biochem. Biophys. Res. Commun. 307, 198-205.
10. Qin, W., Feng, J., Li, Y., Lin, Z. and Shen, B. (2006) Fusion protein of CDR mimetic peptide with Fc inhibit TNF-a induced cytotoxicity. Mol. Immunol. 43, 660-666.
11. Slamon, D. J., Clark, G. M., Wong, S. G., Levin, W. J., Ullrich, A. and McGuire, W. L. (1987) Human breast cancer: correlation of relapse and survival with amplification of the HER-2/neu oncogene. Science 235, 177-182.
12. Slamon, D. J., Godolphin, W., Jones, L. A., Holt, J. A., Wong, S. G., Keith, D. E. (1989) Studies of the HER-2/neu proto-oncogene in human breast and ovarian cancer. Science 244, 707-712.
13. Press, M. F., Bernstein, L., Thomas, P. A., Meisner, L. F., Zhou, J. Y., Ma, Y. (1997) HER-2/neu gene amplification characterized by fluorescence in situ hybridization: poor prognosis in node-negative breast carcinomas. J. Clin. Oncol. 15, 2894-2904.
14. Press, M. F., Slamon, D. J., Flom, K. J., Park, J., Zhou, J. Y. and Bernstein, L. (2002) Evaluation of HER-2/neu gene amplification and overexpression: comparison of frequently used assay methods in a molecularly characterized cohort of breast cancer specimens. J. Clin. Oncol. 20, 3095-3105.
15. Jurado, P., de Lorenzo, V. and Fernández, L. A. (2006) Thioredoxin fusions increase folding of single chain Fv antibodies in the cytoplasm of Escherichia coli: evidence that chaperone activity is the prime effect of thioredoxin. J. Mol. Biol. 357, 49-61.
16. Adams, G. P., Schier, R., McCall, A. M., Simmons, H. H., Horak, E. M., Alpaugh, R. K., Marks, J. D. and Weiner, L. M. (2001) High affinity restricts the localization and tumor penetration of single-chain Fv antibody molecules. Cancer Res. 61, 4750-4755.
17. Carter, P., Presta, L., Gorman, C. M., Ridgway, J. B., Henner, D., Wong, W. L., Rowland, A. M., Kotts, C., Carver, M. E. and Shepard, H. M. (1992) Humanization of an anti-p185HER2 antibody for human cancer therapy. Proc. Natl. Acad. Sci. U.S.A. 89, 4285-4289.
18. Li, B., Wang, H., Da, i. J., Ji, J., Qian, W., Zhang, D., Hou, S. and Guo, Y. (2005) Construction and characterization of a humanized anti-human CD3 monoclonal antibody 12F6 with effective immunoregulation functions. Immunology 116, 487-498.
19. Gao, J., Kou, G., Chen, H., Wang, H., Li, B., Lu, Y., Zhang, D., Wang, S., Hou, S., Qian, W., Dai, J., Zhao, J., Zhong, Y. and Guo, Y. (2008) Treatment of hepatocellular carcinoma in mice with PE38KDEL type I mutant-loaded poly(lactic-co-glycolic acid) nanoparticles conjugated with humanized SM5-1 F(ab') fragments. Mol. Cancer Ther. 7, 3399-3407.
20. Kou, G., Gao, J., Wang, H., Chen, H., Li, B., Zhang, D., Wang, S., Hou, S., Qian, W., Dai, J., Zhong, Y. and Guo, Y. (2007) Preparation and characterization of paclitaxelloaded PLGA nanoparticles coated with cationic SM5-1 single-chain antibody. J. Biochem. Mol. Biol. 40, 731-739.
21. Li, B., Shi, S., Qian, W., Zhao, L., Zhang, D., Hou, S., Zheng, L., Dai, J., Zhao, J., Wang, H. and Guo, Y. (2008) Development of novel tetravalent anti-CD20 antibodies with potent antitumor activity. Cancer Res. 68, 2400-2408.